JP2020530776A5 - - Google Patents
Info
- Publication number
- JP2020530776A5 JP2020530776A5 JP2020520424A JP2020520424A JP2020530776A5 JP 2020530776 A5 JP2020530776 A5 JP 2020530776A5 JP 2020520424 A JP2020520424 A JP 2020520424A JP 2020520424 A JP2020520424 A JP 2020520424A JP 2020530776 A5 JP2020530776 A5 JP 2020530776A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- percentage homology
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023190606A JP7610680B2 (ja) | 2017-06-25 | 2023-11-08 | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524553P | 2017-06-25 | 2017-06-25 | |
| US62/524,553 | 2017-06-25 | ||
| PCT/US2018/039144 WO2019005634A2 (en) | 2017-06-25 | 2018-06-22 | ANTI-PD-L1 ANTIBODIES AND METHODS OF PREPARATION AND USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190606A Division JP7610680B2 (ja) | 2017-06-25 | 2023-11-08 | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530776A JP2020530776A (ja) | 2020-10-29 |
| JP2020530776A5 true JP2020530776A5 (enExample) | 2022-01-17 |
| JP7383605B2 JP7383605B2 (ja) | 2023-11-20 |
Family
ID=64742649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520424A Active JP7383605B2 (ja) | 2017-06-25 | 2018-06-22 | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 |
| JP2023190606A Active JP7610680B2 (ja) | 2017-06-25 | 2023-11-08 | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190606A Active JP7610680B2 (ja) | 2017-06-25 | 2023-11-08 | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11560431B2 (enExample) |
| EP (1) | EP3645738A4 (enExample) |
| JP (2) | JP7383605B2 (enExample) |
| CN (2) | CN116535508A (enExample) |
| WO (1) | WO2019005634A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12098204B2 (en) * | 2018-11-16 | 2024-09-24 | Nanjing GenScript Biotech Co., Ltd. | Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereof |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| AU2021236302A1 (en) * | 2020-03-12 | 2022-10-20 | Immune-Onc Therapeutics, Inc. | Novel anti-LILRB4 antibodies and derivative products |
| JP2024509369A (ja) * | 2021-02-10 | 2024-03-01 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | 抗ｐｄ－ｌ１抗体及びその使用 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| BR112016000853A2 (pt) * | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| AU2014364593A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP4141032B1 (en) * | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| AR105618A1 (es) * | 2015-05-29 | 2017-10-25 | Genentech Inc | Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer |
| KR102763369B1 (ko) * | 2017-06-25 | 2025-02-05 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| SG11202003237QA (en) * | 2017-11-02 | 2020-05-28 | Systimmune Inc | Bispecific antibodies and methods of making and using thereof |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
-
2018
- 2018-06-22 EP EP18823242.5A patent/EP3645738A4/en active Pending
- 2018-06-22 JP JP2020520424A patent/JP7383605B2/ja active Active
- 2018-06-22 WO PCT/US2018/039144 patent/WO2019005634A2/en not_active Ceased
- 2018-06-22 CN CN202310737246.6A patent/CN116535508A/zh active Pending
- 2018-06-22 US US16/615,112 patent/US11560431B2/en active Active
- 2018-06-22 CN CN201880038275.0A patent/CN110831972B/zh active Active
-
2023
- 2023-11-08 JP JP2023190606A patent/JP7610680B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529863A5 (enExample) | ||
| JP2020529862A5 (enExample) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP2020531043A5 (enExample) | ||
| JP2020530776A5 (enExample) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2024037894A5 (enExample) | ||
| AU2022350588A1 (en) | Antibody, antibody-drug conjugate thereof and use thereof | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| WO2021213434A1 (zh) | 一种抗Nectin-4的抗体及其应用 | |
| JP2023509196A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| JP2021515559A5 (enExample) | ||
| JP2021527431A5 (enExample) | ||
| JP2022533418A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| RU2008135132A (ru) | Антитела-антагонисты интерлейкина-17 (ил-17) для лечения рака | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2024532886A5 (enExample) | ||
| JP2021501575A5 (enExample) | ||
| CN110831972A (zh) | 抗pd-l1抗体及其制备和使用方法 | |
| EP4242231A1 (en) | Anti-siglec-15 antibody and application thereof in preparing drug | |
| CN119053607B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |